EP1292189A2 - Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal - Google Patents

Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Info

Publication number
EP1292189A2
EP1292189A2 EP01937205A EP01937205A EP1292189A2 EP 1292189 A2 EP1292189 A2 EP 1292189A2 EP 01937205 A EP01937205 A EP 01937205A EP 01937205 A EP01937205 A EP 01937205A EP 1292189 A2 EP1292189 A2 EP 1292189A2
Authority
EP
European Patent Office
Prior art keywords
bacteria
gram
glutamine composition
composition
glutamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01937205A
Other languages
German (de)
French (fr)
Other versions
EP1292189A4 (en
Inventor
Pinaki Panigrahi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP1292189A2 publication Critical patent/EP1292189A2/en
Publication of EP1292189A4 publication Critical patent/EP1292189A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

A composition and method for treating and preventing gastro-intestinal injury are disclosed. The composition includes a combination of Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃ and/or ∫i⊃Bifidobacteria∫/i⊃, and glutamine. The method involves orally or naso-gastrically administering a composition containing Gram (+) bacteria, in particular ∫i⊃Lactobacillus∫/i⊃, and glutamine. The composition, which blocks translocation of bacterial agents such as Gram (-) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of symptoms and/or disease that result from translocation of Gram (-) bacteria, including inflammation in the gastro-intestinal tract, Neonatal Necrotizing Enterocolitis (NEC) and bacterial sepsis.

Claims

WHAT IS CLAIMED IS:
1. A method of preventing gastro-intestinal dysfunction comprising orally administering a Gram (+) bacteria and glutamine composition.
2. The method of claim 1, wherein said Gram (+) bacteria and
glutamine composition protects tissues along the gastro-intestinal tract by
blocking bacteria or other agent adherence to mucosal layers and by blocking bacteria or other agent translocation across said mucosal layers.
3. The method of claim 2, wherein translocation of agents selected
from the group consisting of infectious agents, toxins, chemicals, and injurious
substances is blocked.
4. The method of claim 1, further comprising optimizing mucosal
defense due to an intraluminal/apical presence ofthe Gram (+) bacteria and
glutamine composition.
5. The method of claim 1 wherein the administering comprises
administering to individuals selected from a group consisting of pre-term infants,
full-term infants, children and adults.
6. The method of claim 1 wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition as a powder.
7. The method of claim 1, wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition mixed in a fluid.
8. The method of claim 1 , wherein the administering comprises
administering the Gram (+) bacteria and glutamine composition as capsules.
-20-
9. The method of claim 8, wherein the capsules are acid-resistant
slow-release micro-capsules.
10. The method of claim 8, wherein the capsules are coated acid-
resistant slow-release capsules.
11. The method of claim 1 , further comprising administering other
drugs for treatment of gastro-intestinal ailments with the Gram (+) bacteria and
glutamine composition.
12. The method of claim 2, wherein the blocking bacterial
translocation comprises blocking Gram (-) bacteria..
13. A method of preventing gastro-intestinal dysfunction characterized
by infection or inflamation comprising orally administering a Gram (+) bacteria
and glutamine composition and allowing the Gram (+) bacteria and glutamine
composition to coat gastro-intestinal mucosa.
14. The method of Claim 13, further comprising preventing conditions
selected from the group consisting of NEC and bacterial sepsis.
15. A Gram (+) bacteria and glutamine composition.
16. The Gram (+) bacteria and glutamine composition of Claim 15,
said Gram (+) bacteria and glutamine composition blocks epithelial cell bacterial
adherence and translocation.
17. A vaccine prepared using the Gram (+) bacteria and glutamine
composition of Claim 15.
-21-
EP01937205A 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal Withdrawn EP1292189A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20140800P 2000-05-03 2000-05-03
US201408P 2000-05-03
PCT/US2001/014080 WO2001083700A2 (en) 2000-05-03 2001-05-03 Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Publications (2)

Publication Number Publication Date
EP1292189A2 true EP1292189A2 (en) 2003-03-19
EP1292189A4 EP1292189A4 (en) 2003-08-13

Family

ID=22745700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01937205A Withdrawn EP1292189A4 (en) 2000-05-03 2001-05-03 Oral gram (+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal

Country Status (4)

Country Link
EP (1) EP1292189A4 (en)
AU (1) AU2001262966A1 (en)
CA (1) CA2407724A1 (en)
WO (1) WO2001083700A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114419D0 (en) * 2001-06-13 2001-08-08 Mars Uk Ltd Health food
SE526711C2 (en) 2003-01-31 2005-10-25 Probi Ab Novel strains of Bifidobacterium having ability to survive in intestinal tract and produce glutamine and arginine in vivo, useful for preparing medicament for treatment of intensive care patients with intestinal failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5533973A (en) * 1995-01-13 1996-07-09 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US5707353A (en) * 1995-12-21 1998-01-13 Abbott Laboratories Oral administration of beneficial agents
US5981590A (en) * 1997-03-17 1999-11-09 Probiotix, Inc. Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
WO1999055326A1 (en) * 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007808A (en) * 1995-06-23 1999-12-28 Dibra S.P.A. Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROTH E ET AL: "GLUTAMIN: WIRKUNGEN AUF DAS IMMUNOSYSTEM, AUF EIWEISSHAUSHALT UND DARMFUNKTIONEN" WIENER KLINISCHE WOCHENSCHRIFT, NEW YORK, NY, US, vol. 108, no. 21, 1996, pages 669-676, XP000937773 ISSN: 0043-5325 *
See also references of WO0183700A2 *

Also Published As

Publication number Publication date
WO2001083700A2 (en) 2001-11-08
EP1292189A4 (en) 2003-08-13
CA2407724A1 (en) 2001-11-08
WO2001083700A3 (en) 2002-02-07
AU2001262966A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
US8853269B2 (en) Composition and method for treating infections and promoting intestinal health
ES2326933T3 (en) ENTERIC FORMULATIONS OF COMPOSITIONS OF ANTIDIARARIC PROANTOCIANIDINE POLYMERS.
US8003118B2 (en) Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
AU2001244611B2 (en) Preparations for preventing bile acid diarrhea
US5631022A (en) Picosulfate dosage form
JP3425441B2 (en) Treatment of non-inflammatory and non-infectious bowel disorders
Turck et al. Comparison of racecadotril and loperamide in children with acute diarrhoea
US20120053239A1 (en) Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate
JP2009537547A (en) Biological therapeutic compositions and uses thereof
WO2002053190A3 (en) Particles for inhalation having sustained release properties
JPH07505901A (en) Synergistic combination of a substance that inhibits gastric acid secretion and an acid-degradable antibiotic
EP0589893A1 (en) Pharmaceutical compositions against gastric disorders.
CN109893516A (en) For treating the pharmaceutical composition of helicobacter pylori
WO2018136490A1 (en) Compositions and methods for common colds
JP2005501862A (en) One-time dosage of azithromycin
US20060210483A1 (en) Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
JPS62145022A (en) Drug for food poisoning
WO2001083700A2 (en) Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal
JPH07242560A (en) Antimicrobial
JP4933000B2 (en) Anti-Helicobacter pylori
Nord Effect of quinolones on the human intestinal microflora
CN111184867A (en) Chemical medicine composition for treating helicobacter pylori infection
AU749509B2 (en) Use of triclosan for the treatment of helicobacter pylori infections
CN1951386A (en) Medicinal combinations composed by meropenem with three kinds of sputum removing medicament respectively
WO2007067663A1 (en) Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041201